We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RPRX market cap is 19.03B. The company's latest EPS is USD 1.4901 and P/E is 22.39.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 473.57M | 567.98M | 583.49M | 622.37M | 489.74M |
| Operating Income | 468.93M | -87.92M | 317.55M | 803.16M | 287.74M |
| Net Income | 494.34M | 4.78M | 102M | 543.99M | 208.21M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.12B | 2.29B | 2.24B | 2.35B | 2.26B |
| Operating Income | 1.64B | 1.41B | 913.92M | 1.5B | 1.32B |
| Net Income | 975.04M | 619.73M | 42.83M | 1.13B | 858.98M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 16.38B | 16.13B | 17.66B | 18.04B | 18.22B |
| Total Liabilities | 6.3B | 6.27B | 7.9B | 7.78B | 7.88B |
| Total Equity | 10.08B | 9.86B | 9.75B | 10.26B | 10.34B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 16.02B | 17.52B | 16.81B | 16.38B | 18.22B |
| Total Liabilities | 6.12B | 7.27B | 7.29B | 6.3B | 7.88B |
| Total Equity | 9.9B | 10.25B | 9.53B | 10.08B | 10.34B |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 2.99B | 664.64M | 1.32B | 2.03B | 2.77B |
| Investing | -2.07B | -86.65M | -979.83M | -2.17B | -2.68B |
| Financing | -2.15B | -212M | 944.61M | 619.11M | 361.15M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 2.03B | 2.02B | 2.14B | 2.99B | 2.77B |
| Investing | -2.76B | -1.87B | -1.03B | -2.07B | -2.68B |
| Financing | 1.49B | 385.11M | -944.86M | -2.15B | 361.15M |
| Market Cap | 19.03B |
| Price to Earnings Ratio | 22.39 |
| Price to Sales Ratio | 8.5 |
| Price to Cash Ratio | 20.71 |
| Price to Book Ratio | 1.86 |
| Dividend Yield | 2.67% |
| Shares Outstanding | 576.45M |
| Average Volume (1 week) | 5.22M |
| Average Volume (1 Month) | 4.76M |
| 52 Week Change | 5.87% |
| 52 Week High | 34.20 |
| 52 Week Low | 24.05 |
| Spread (Intraday) | 3.7 (10.3%) |
| Company Name | Royalty Pharma PLC |
| Address |
the pavilions bridgwater road bristol BS13 8AE |
| Website | https://www.royaltypharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
